Ulka Vaishampayan, MD, discusses the excitement surrounding PSMA radioligand therapy in the prostate cancer space.
Ulka aishampayan, MD, professor of oncology at Wayne State University, and chief of the Solid Tumor Program at Barbara Ann Karmanos Cancer Institute, discusses the excitement surrounding PSMA radioligand therapy in the prostate cancer space.
This is a promising advance that is eagerly awaited for the treatment of patients with metastatic castration-resistant prostate cancer, Vaishampayan says. The FDA’s recent approval of Gallium 68 PSMA-11 (Ga 68 PSMA-11), marking the first ever drug for positron emission tomography (PET) imaging of PSMA positive lesions in men with prostate cancer, allows for the detection of early evidence of metastasis, and this can also help physicians make better treatment decisions for patients.
In regard to the PSMA radioligand therapy, preliminary data in both Australia and Germany have established the safety and efficacy of this treatment. Overall, Vaishampayan says this is an intriguing and exciting opportunity, and the PSMA radioligand therapy will move the field forward. She also notes that this therapeutic approach appears to be easier to tolerate than chemotherapy and will allow for 1 more option that is relatively tolerable for patients with prostate cancer.